Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Stopping methotrexate might reverse lymphoma-like conditions in some patients.

This review concludes that methotrexate remains an effective and safe first-line treatment for various inflammatory and immune-mediated skin conditions in children, despite the rise of biologic therapies.

This article lists the clinically important interactions and skin reactions of several drugs and substances, including THA, FK506, tamoxifen, tamsulosin, tartrazine, tea tree oil, temazepam, and temozolomide, but provides no new clinical results.

This meta-analysis and systematic review found that botulinum toxin injections significantly increased hair count in patients with androgenetic alopecia compared to controls, indicating promising efficacy and good safety.

In this study, bicalutamide at low doses was not linked to significant liver enzyme changes compared to other androgen-blocking treatments in transfeminine adolescents and young adults, suggesting its safety with careful monitoring for this population over one year.

This study found no increased frequency of the TNF2 allele in Mexican patients with adverse cutaneous drug reactions mediated by delayed hypersensitivity, suggesting its lower relevance compared to findings in Caucasian populations.

This article reviews the literature on the off-label use of botulinum toxin for dermatological conditions, highlighting its potential effectiveness in treating rosacea, anal fissures, Raynaud phenomenon, hypertrophic scars, keloids, and hidradenitis suppurativa.

Among men with androgenetic alopecia, this study found that taking 5 mg of KX-826 twice daily significantly increased hair count compared to a placebo, with the treatment being well-tolerated and no serious adverse effects reported.

Some patients on anti-TNF drugs experience a type of hair loss called TAIAPA.

This systematic review suggests that botulinum toxin may be effective for treating certain scalp conditions, but the current evidence varies widely in quality and often derives from small observational studies.

This study found that low-dose methotrexate significantly reduced the steroid requirement in subjects with corticosteroid-requiring asthma without altering their clinical status or causing significant complications.

This study found that Bokusoku extract and its compound pentagalloyl glucose inhibited testosterone metabolism and sebum synthesis, suggesting potential therapeutic use for androgen-related acne.

This study identified ISX9 as a novel agonist of the Wnt/β‐catenin pathway, which promoted hair regrowth in mice and may offer a therapeutic approach for alopecia.

In this study, botulinum toxin type A did not improve clinical features in patients with recalcitrant alopecia totalis or alopecia universalis over a four-month period.

Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.

This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.

This case report describes a rare occurrence of injection site reactions in a 77-year-old woman with eosinophilic fasciitis using subcutaneous methotrexate, marking the first documented instance in this patient population.

The Paxbp1 gene is crucial for healthy hair follicles.

This study found that co-drugs synthesized from hydroquinone and tranexamic acid improved skin targeting and deposition, with reduced irritation and enhanced efficacy for treating hyperpigmentation.

In this prospective study, 15 patients with patchy alopecia areata treated with intralesional methotrexate every two weeks showed a significant improvement in hair regrowth and reduction in lesion severity, with changes linked to decreased tissue levels of TNF-α.

Some medications for inflammation can cause a condition with scalp rashes and hair loss, often linked to Crohn's disease, and may require treatment changes to prevent permanent hair loss.

This study found that oral administration of Terminalia bellirica enhanced hair growth in testosterone-suppressed conditions in both human cell and mouse models, outperforming finasteride, a current commercial hair loss treatment.

This study found that ISX9 may activate the Wnt/β-catenin signaling pathway and holds potential as a therapeutic agent for treating alopecia.

This phase I study reported that ETC-159, targeting Wnt signalling, showed tolerable safety profiles at doses that inhibit its pathway, though bone turnover markers increased, warranting early and regular monitoring. No tumor responses were observed, but two patients achieved stable disease for several cycles.

In this retrospective study, low-dose methotrexate was observed to be effective and well-tolerated in treating recalcitrant alopecia areata multiplex, achieving complete or near-complete hair regrowth in about 90% of patients despite some experiencing elevated liver enzymes and gastrointestinal discomfort.

This case report describes a woman with trichotillomania who experienced marked improvement and hair regrowth after off-label onabotulinumtoxinA treatment.

This review examines current literature on botulinum toxin type A for androgenetic alopecia, reporting an association with increased hair growth and improved hair density, though further research is needed.

This review examines adipose-derived stem cells as a promising therapy for alopecia but reports no new clinical results, discussing their potential mechanisms and the challenges faced in treatment development.

This study explains that while trichothiodystrophy and xeroderma pigmentosum share genetic defects, TTD patients primarily exhibit issues in transcription initiation, not the increased skin cancer risk seen in XP.